Related Experiment Videos
HER2 testing recommendations in Australia
M Bilous1,
1Tissue Pathology Department, ICPMR, Westmead Hospital, NSW, Australia. michaelb@icpmr.wsahs.nsw.gov.au
Abstract:
HER2 is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody trastuzumab (Herceptin). Since only around 20% of breast cancers carry the overexpressed HER2 receptor protein to which this treatment is directed, patient selection is very important in determining eligibility for the drug. Currently, immunohistochemistry and fluorescence in situ hybridisation are the main tests used for HER2 detection, and these testing recommendations have been developed based on national and international data.
Insights
Trastuzumab (Herceptin) targets HER2-positive metastatic breast cancer. Accurate HER2 detection is crucial for patient selection, as only 20% of breast cancers overexpress this receptor. Current testing methods include immunohistochemistry and fluorescence in situ hybridization.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Diagnostics
Background:
- Metastatic breast cancer treatment has advanced with targeted therapies.
- Humanized monoclonal antibody trastuzumab (Herceptin) targets the HER2 receptor.
- HER2 overexpression is present in approximately 20% of breast cancers, necessitating precise patient identification.
Purpose of the Study:
- To highlight the importance of patient selection for HER2-targeted therapy.
- To discuss the role of HER2 detection in eligibility for trastuzumab treatment.
- To review current diagnostic methods for HER2 detection.
Main Methods:
- Review of diagnostic techniques for HER2 detection.
- Analysis of patient selection criteria for trastuzumab therapy.
- Consideration of national and international testing recommendations.
Main Results:
- Trastuzumab efficacy is linked to HER2 receptor status.
- Accurate HER2 testing is paramount for identifying eligible patients.
- Immunohistochemistry and fluorescence in situ hybridization are established HER2 detection methods.
Conclusions:
- Effective use of trastuzumab in metastatic breast cancer relies on accurate HER2 detection.
- Patient selection based on HER2 status is critical for treatment success.
- Established testing protocols guide HER2 detection and patient eligibility.